Rivaroxaban (Xarelto®): Guide de la pratique officinale

J Douxfils; S Michel; C Beauloye; M Goethals; P Hainaut; H Heidbuchel; C Hermans; B Ickx; K Jochmans; S Mottes; F Mullier; A Peeters; C Scavée; P Sinnaeve; M Sprynger; V Thijs; C Vandenbroeck; E Vandermeulen; P Verhamme; J M Dogné

Rivaroxaban (Xarelto®): Guide de la pratique officinale

J Douxfils, S Michel, C Beauloye, M Goethals, P Hainaut, H Heidbuchel, C Hermans, B Ickx, K Jochmans, S Mottes, F Mullier, A Peeters, C Scavée, P Sinnaeve, M Sprynger, V Thijs, C Vandenbroeck, E Vandermeulen, P Verhamme, J M Dogné

Résultats de recherche: Contribution à un journal/une revue › Article de revue › Revue par des pairs

976 Téléchargements (Pure)

Résumé

Rivaroxaban is one of the new oral anticoagulants (NOACs) (recommended as reference treatments when a long-term anticoagulation is needed). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto® in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.

Titre traduit de la contribution	Rivaroxaban: Xarelto® - Recommendations for pharmacists
langue originale	Français
Pages (de - à)	28-36
Nombre de pages	9
journal	Journal de Pharmacie de Belgique
Numéro de publication	1
Etat de la publication	Publié - 1 mars 2013

Accès au document

Journ. Ph. Belg. 2013 - Guide pratique du rivaroxabanVersion finale publiée, 900 KB

Autres fichiers et liens

Link to publication in Scopus

Evaluation of thrombotic and/or bleeding risks associated with anticoagulotherapy.
Auteur: Douxfils, J., 24 oct. 2015
Superviseur: Dogne, J. (Promoteur), Mullier, F. (Promoteur), Masereel, B. (Président), Chatelain, B. (Jury), Chatelain, C. (Personne externe) (Jury), Verhamme, P. B. (Personne externe) (Jury), TEN CATE, H. (Personne externe) (Jury) & Ageno, W. (Personne externe) (Jury)
Student thesis: Doc types › Docteur en Sciences Biomédicales et Pharmaceutiques

Contient cette citation

Douxfils, J., Michel, S., Beauloye, C., Goethals, M., Hainaut, P., Heidbuchel, H., Hermans, C., Ickx, B., Jochmans, K., Mottes, S., Mullier, F., Peeters, A., Scavée, C., Sinnaeve, P., Sprynger, M., Thijs, V., Vandenbroeck, C., Vandermeulen, E., Verhamme, P., & Dogné, J. M. (2013). Rivaroxaban (Xarelto®): Guide de la pratique officinale. Journal de Pharmacie de Belgique, (1), 28-36.

@article{b0392481c05a4b8197c9baf853e7f3bb,

title = "Rivaroxaban (Xarelto{\textregistered}): Guide de la pratique officinale",

abstract = "Rivaroxaban is one of the new oral anticoagulants (NOACs) (recommended as reference treatments when a long-term anticoagulation is needed). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto{\textregistered} in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.",

keywords = "Anticoagulants, Humans, Morpholines, Pharmacists, Thiophenes, Venous Thrombosis, Vitamin K",

author = "J Douxfils and S Michel and C Beauloye and M Goethals and P Hainaut and H Heidbuchel and C Hermans and B Ickx and K Jochmans and S Mottes and F Mullier and A Peeters and C Scav{\'e}e and P Sinnaeve and M Sprynger and V Thijs and C Vandenbroeck and E Vandermeulen and P Verhamme and Dogn{\'e}, {J M}",

year = "2013",

month = mar,

day = "1",

language = "Fran{\c c}ais",

pages = "28--36",

journal = "Journal de Pharmacie de Belgique",

issn = "0047-2166",

publisher = "APB Algemene Pharmaceutische Bond",

number = "1",

}

Douxfils, J, Michel, S, Beauloye, C, Goethals, M, Hainaut, P, Heidbuchel, H, Hermans, C, Ickx, B, Jochmans, K, Mottes, S, Mullier, F, Peeters, A, Scavée, C, Sinnaeve, P, Sprynger, M, Thijs, V, Vandenbroeck, C, Vandermeulen, E, Verhamme, P & Dogné, JM 2013, 'Rivaroxaban (Xarelto®): Guide de la pratique officinale', Journal de Pharmacie de Belgique, Numéro 1, p. 28-36.

TY - JOUR

T1 - Rivaroxaban (Xarelto®)

T2 - Guide de la pratique officinale

AU - Douxfils, J

AU - Michel, S

AU - Beauloye, C

AU - Goethals, M

AU - Hainaut, P

AU - Heidbuchel, H

AU - Hermans, C

AU - Ickx, B

AU - Jochmans, K

AU - Mottes, S

AU - Mullier, F

AU - Peeters, A

AU - Scavée, C

AU - Sinnaeve, P

AU - Sprynger, M

AU - Thijs, V

AU - Vandenbroeck, C

AU - Vandermeulen, E

AU - Verhamme, P

AU - Dogné, J M

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Rivaroxaban is one of the new oral anticoagulants (NOACs) (recommended as reference treatments when a long-term anticoagulation is needed). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto® in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.

AB - Rivaroxaban is one of the new oral anticoagulants (NOACs) (recommended as reference treatments when a long-term anticoagulation is needed). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto® in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.

KW - Anticoagulants

KW - Humans

KW - Morpholines

KW - Pharmacists

KW - Thiophenes

KW - Venous Thrombosis

KW - Vitamin K

UR - http://www.scopus.com/inward/record.url?scp=84876403985&partnerID=8YFLogxK

M3 - Article de revue

C2 - 23638610

SN - 0047-2166

SP - 28

EP - 36

JO - Journal de Pharmacie de Belgique

JF - Journal de Pharmacie de Belgique

IS - 1

ER -

Rivaroxaban (Xarelto®): Guide de la pratique officinale

Résumé

Accès au document

Autres fichiers et liens

Empreinte digitale

Thèses de l'étudiant

Evaluation of thrombotic and/or bleeding risks associated with anticoagulotherapy.

Contient cette citation